Thrombosis and Bleeding in Cancer Patients

Korte, Wolfgang

doi:10.1007/978-3-319-90990-5_19

Cited by 1 publication

(1 citation statement)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Routine laboratory coagulation tests such as thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fbg), and Ddimer are commonly used to detect coagulation disorders [7]. Furthermore, hyperhomocysteinemia [8] and activated protein C resistance (APCR) have an association with venous thromboses in patients with cancer [9].…”

Section: Introductionmentioning

confidence: 99%

Thrombophilia in hepatocellular carcinoma

Selim

Abdalla

Hosny

2019

Egypt Liver Journal

View full text Add to dashboard Cite

Background: Chronic liver disease and hepatocellular carcinoma (HCC) can cause a disturbance in the coagulation system. In this study, we aimed to assess the risk factors for venous thromboembolism either acquired or hereditary in patients with HCC. Results: Serum levels of proteins C and S, AT activity, and lipoprotein (a) were significantly lower in both HCC and cirrhotic patients while homocysteine levels were significantly higher in HCC patients. The prevalence of activated protein C resistance (APCR) and factor V Leiden (FVL) mutation was higher in HCC patients but with no significant differences between the studied groups. With multivariate analysis, prothrombin time, Fbg, protein C and S deficiency, increased lipoprotein (a), hyperhomocysteinemia, APCR, and FVL mutation were independent risk factors for thromboembolic complications in HCC patients. Conclusions: Thrombophilic abnormalities are prevalent in HCC patients, and they have a substantial increased risk of venous thromboembolism. Patients and methodsData were collected from cirrhotic patients with and without HCC, who were admitted to the Hepato-

show abstract

Section: Introductionmentioning

confidence: 99%